Opinion|Videos|November 14, 2023
The Role of Biomarker and Molecular Testing in CRC
Drs Wu, Ciombor, and Cohen discussed upfront molecular testing in patients with colorectal cancer to guide treatment, with Dr Ciombor reviewing HER2 testing methods and Dr Cohen noting liquid biopsy limitations.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5